SuperworthAgilent Technologies, Inc. A
Medical - Diagnostics & Research, Healthcare
$169.09
−0.14%
- Market cap
- $47.7B
- PE
- 33.3×
- 10y median 32.4×
- Forward PE
- Price to sales
- 6.5×
- EV/EBIT
- 30.4×
- Revenue, 12 months
- $7.4B
- +9% on a year ago
- Net margin
- 19.5%
- Free cash flow yield
- 2.7%
Agilent Technologies trades at 33.3× trailing earnings, near its ten-year median. Revenue was $7.4B over the last twelve months, up 9% on a year earlier with a 20% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.7B | $1.7B | $1.6B | $1.6B | $1.7B+1% | $1.7B+1% | $1.7B+6% | $1.7B+10% | $1.9B+9% | $1.8B+7% | $1.8B+10% | $1.9B+8% | |
| Cost of revenue | $773M | $750M | $717M | $723M | $785M+2% | $782M+4% | $802M+12% | $850M+18% | $871M+11% | $852M+9% | $845M+5% | $836M−2% |
| Gross profit | $915M | $908M | $856M | $855M | $916M+0% | $899M−1% | $866M+1% | $888M+4% | $990M+8% | $946M+5% | $990M+14% | $1B+17% |
| R&D | $114M | $128M | $113M | $127M | $111M−3% | $113M−12% | $112M−1% | $111M−13% | $119M+7% | $117M+4% | $126M+13% | $123M+11% |
| SG&A | $393M | $396M | $380M | $395M | $397M+1% | $410M+4% | $454M+20% | $417M+6% | $428M+8% | $476M+16% | $465M+2% | $475M+14% |
| $408M | $384M | $363M | $333M | $408M+0% | $376M−2% | $300M−17% | $360M+8% | $443M+9% | $353M−6% | $399M+33% | $444M+23% | |
| Interest expense | $22M | $22M | $20M | $22M | $32M+46% | $28M+27% | $29M+45% | $28M+27% | $27M−16% | $25M−11% | $25M−14% | $29M+4% |
| Pre-tax income | $420M | $403M | $374M | $343M | $401M−5% | $367M−9% | $260M−31% | $366M+7% | $442M+10% | $364M−1% | $408M+57% | $444M+21% |
| −$55M | $55M | $66M | $61M | $50M | $49M−11% | $45M−32% | $30M−51% | $8M−84% | $59M+20% | $69M+53% | $82M+173% | |
| Net income | $475M | $348M | $308M | $282M | $351M−26% | $318M−9% | $215M−30% | $336M+19% | $434M+24% | $305M−4% | $339M+58% | $362M+8% |
| $1.62 | $1.18 | $1.05 | $0.97 | $1.22−25% | $1.11−6% | $0.75−29% | $1.18+22% | $1.53+25% | $1.07−4% | $1.20+60% | $1.28+9% | |
| 293M | 294M | 293M | 291M | 291M−1% | 287M−2% | 285M−3% | 285M−2% | 284M−2% | 284M−1% | 283M−1% | 283M−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Agilent Technologies's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $40.4B | 35.6× | 35.0× | 6.1× | +7% | 15.0% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .